POSC284 The Acceptance of Minimal Residual Disease (MRD) as a Clinical Endpoint in Multiple Myeloma (MM): A Targeted Literature Review

Abstract

Authors

W Grandy P Kachouh B Yang

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×